Contrastingly, the expression of DLAT was shown to be low in nine different malignancies: breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), colon adenocarcinoma/rectum adenocarcinoma (COADREAD), head and neck squamous cell carcinoma (HNSC), pan-kidney cohort (KIPAN), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), prostate adenocarcinoma (PRAD), and thyroid carcinoma (THCA). This evidence concerns the gene DLAT and invasive breast carcinoma.